Denosumab found to increase cardiovascular risk in dialysis-dependent patients

Denosumab found to increase cardiovascular risk in dialysis-dependent patients

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) compared with oral bisphosphonates, according to a study published online Jan. 7 in the Annals of Internal Medicine.